Free Trial

REGENXBIO Q4 2022 Earnings Report

REGENXBIO logo
$7.37 +0.22 (+3.08%)
As of 01/17/2025 04:00 PM Eastern

REGENXBIO EPS Results

Actual EPS
-$1.38
Consensus EPS
-$1.48
Beat/Miss
Beat by +$0.10
One Year Ago EPS
$6.67

REGENXBIO Revenue Results

Actual Revenue
$31.35 million
Expected Revenue
$37.45 million
Beat/Miss
Missed by -$6.10 million
YoY Revenue Growth
-92.10%

REGENXBIO Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

REGENXBIO Earnings Headlines

RegenXBio: Strategic Partnerships and Promising Pipeline Drive Buy Rating
He’s without a doubt the best stock picker we’ve ever met.
There are very few people in this world who are considered “the best” in their field. There are guys like Michael Jordan who is considered the best basketball player of all time… Or Warren Buffet who is considered the best Investor of all time… But we’ve just met a man who might be the best stock picker of all time… Right now, as we speak, he is currently ranked the #1 stock picker in North America.
See More REGENXBIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like REGENXBIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on REGENXBIO and other key companies, straight to your email.

About REGENXBIO

REGENXBIO (NASDAQ:RGNX), a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

View REGENXBIO Profile

More Earnings Resources from MarketBeat